Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Melanoma 1Leukemia, Hairy Cell 1Histiocytosis 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 23Cisplatin 16pembrolizumab 6Fluorouracil 6pemigatinib 4Radiotherapy 3Oxaliplatin 3Leucovorin 3Drug Therapy 3infigratinib 2durvalumab 2ceritinib 2aldesleukin 2Radiosurgery 2Photochemotherapy 2Nivolumab 2Liver Transplantation 2Dexamethasone 2Cholangiopancreatography, Endoscopic Retrograde 2Carboplatin 2Capecitabine 2trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1spartalizumab 1seribantumab 1perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane) 1peginterferon alfa-2b 1pazopanib 1padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cholangiocarcinoma × PLX8394 × Clear all
NCT02012231 2020-10-19

Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.

Fore Biotherapeutics

Phase 1 Terminated
5 enrolled
DermatologicEndocrineGastrointestinalHead & NeckMyeloidOther hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Leukemia, Hairy Cell, Melanoma, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis, Cholangiocarcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡